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Breast ductal lavage provides a source of both cells and
fluid from the breast in a non-invasive manner. The fluid
contains freely diffusible steroid hormones and other fac-
tors that may be secreted or released from the epithelial
cells that line the alveoli and ducts of the breast as well as
from myoepithelial cells, stomal cells, and immune cells
that populate the breast. The purpose of the present study
was to determine how perturbations of the system are
reflected in ductal lavage fluid (DLF). We examined
changes associated with menopausal status, tamoxifen
treatment, and Gail model breast cancer risk scores.
Methods
Subjects
Subjects were recruited from the Bluhm Family Program
for Breast Cancer Early Detection and Prevention, at the
Lynn Sage Breast Center of Northwestern Memorial Hos-
pital. Data on known breast cancer risk factors were used
to estimate the 5-year breast cancer risk using the Gail
model. Eligible women included (a) unaffected healthy
women with a 5-year risk estimate of >1.6 and (b) women
with breast cancer who had not received treatment. Only
the contralateral breast was sampled in the latter group.
The number of patients treated with tamoxifen was 29. A
ductal lavage (DL) was performed under local anesthesia
in the office setting according to established methods.
Women were informed of the cytologic findings and
allowed to choose tamoxifen therapy at a dose of 20 mg
daily, or observation (OBS group). None had taken
tamoxifen (TAM) or dietary supplements for prevention.
All subjects were asked to return for DL 6 months after the
first procedure (follow-up lavage). The day of the men-
strual cycle was estimated in premenopausal women
based on the last menstrual period and the typical length
of menstrual cycles among women who had had regular
menstrual cycles of 26 to 32 days.
Samples and laboratory analyses
The lavage effluent was collected in Cytolyte (Cytyc) and
was made up to a final volume of 20 ml. Of this 10 ml was
taken for analysis of hormones and other analytes in the
fluid. The methanol component was removed in a centrif-
ugal evaporator and sample volume was reduced to 4 ml
by lyophillization. Unconjugated steroids were extracted
into ethyl acetate-hexane (3:2) and the aqueous fraction
was kept for steroid sulfates and proteins. Estrogens were
separated from non-phenolic steroids by solvent parti-
tion. All analytes were measured by immunoassays. TAM
and 4-hydroxytamoxifen concentrations in plasma and
NAF were determined by liquid chromatography-tandem
mass spectrometry. Data are expressed in terms of the con-
tent of the lavage.
Statistical analysis
All data except 5-year breast cancer risk estimates were
transformed to their natural logarithms. This provided
adequate normalization for parametric analyses. The
means, ranges, standard deviations were calculated for
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pre- and postmenopausal groups and for TAM and control
treatments. The intraclass correlation coefficients (ICCs)
were calculated for values between subjects (average of
both breasts) between breasts and between ducts (both
breasts) for the baseline samples. Relationships between
DLF analytes and breast cancer risk estimates were deter-
mined by a multiple stepwise backward regression proce-
dure with probability of entry or removal of 0.1 using the
SYSTAT v11 statistical package, Richmond, CA.
Results
Variability estimates
Variation among data obtained between breasts and
between visits was determined for first visits (prior to
treatment) of all patients. The ICCs between visits (six
months apart) were generally as low as those between
breasts, indicating stability of measurements over time.
The between-subject variance represented, on average,
approximately 50% of the total variance and was not dif-
ferent between pre- and postmenopausal women.
Pre- and postmenopausal comparison
A comparison of the geometric mean contents of the ana-
lytes in DLF from pre- and postmenopausal women (ini-
tial visits) was made. Values of androstenedione, DHEA,
and DHEA sulfate in postmenopausal women were highly
significantly lower than those of premenopausal women
(Bonferroni adjusted P values were all <0.001). The mean
values for E2 and estrone sulfate were lower in postmeno-
pausal than in premenopausal women (17.4% and
10.7%, respectively) but not significantly so. Differences
in other analytes were not significant. The range of natural
log of E2 values was 0.45 to 6.91. The natural log of E2
increased significantly with age in DLF of the premeno-
pausal women. The equation with its standard errors was:
Age = 1.02 ± 0.48 (ln E2) + 41.6 ± 2.2 years (regression, P
= 0.04).
TAM concentrations
Tamoxifen concentrations in plasma were approximately
20-times greater than that of 4-OHT. The ratio of 4-OHT
to TAM in the DLF was 4-times higher than that in plasma.
Effect of TAM on hormone concentrations
The median age of women who chose TAM was 54 yr; the
median BMI was 27.1 kg/m2, not significantly different
from those who chose OBS. The mean Gail score was also
not different between the groups. TAM significantly
increased the amount of androstenedione and DHEA in
the lavage fluid (Bonferroni adjusted P values are 0.040
and 0.037, respectively). The unadjusted P value for cathe-
psin D was 0.039 but after adjustment for the number of
comparisons, it was not significant. A paired comparison
of 10 subjects who had samples from both initial and 6
months following TAM visits revealed a 3-fold increase
(Bonferroni adjusted P = 0.02) in E2 in DLF during TAM
treatment. Other analytes were not different from the
group comparisons. Comparisons between first and sec-
ond visits in the OBS group resulted in no significant dif-
ferences in any analytes.
Relation of analytes to risk estimates
The association between biochemical DLF factors and
Gail breast cancer risk estimates were evaluated by multi-
ple stepwise backward regression. In premenopausal
women, DLF analytes accounted for 47.1% of the variabil-
ity in breast cancer risk estimates. Among the variables,
cathepsin D was most significantly related to risk in a neg-
ative relationship and DHEA sulfate was next in signifi-
cance as a positive factor. In postmenopausal women
28.7% of the variability in breast cancer risk scores was
accounted for by the analytes in the multiple regression
model. Here androstenedione was significantly positively
related to Gail scores and DHEA was negatively related.
Relation of estrogen precursors to E2 levels
Androgens and estrone sulfate are potential precursors of
E2 in the breast. Overall the squared multiple R value was
less for pre- than for postmenopausal subjects, 0.269 vs
0.405, respectively. In premenopausal women DLF
estrone sulfate was most highly associated with DLF E2;
the association with individual androgens was lower. In
postmenopausal women the overall association was
higher; androstenedione had the highest association and
DHEA sulfate contributed as well.
Summary
These analyses of ductal lavage fluid provide us with a pic-
ture of the endocrine environment of the breast which is
similar to that provided in our previous studies of nipple
aspirate fluid, but we do not see any significant advan-
tages of DLF over NAF in the measurement of these endo-
crine parameters. However, they support the concept that
the local breast environment is a rich source of markers of
risk, and measures of the efficacy of preventive interven-
tions which in the future will provide the underpinnings
of biologically targeted breast cancer prevention.